Alpha-Synuclein, E46K mutant-rPeptide Introduces new peptide for Parkinson research
MW: 14,459 Da
Description:
Lyophilized powder. Purity >95% by SDS-PAGE and Mass Spec. A point mutantion (E46K) of Alpha-Synuclein gene that has been linked to autosomal dominant early onset Parkinson’s Disease (PD
References:
Zarranz, J.J., et. al. 2004, Ann Neurol. 55, 164
http://www.rpeptide.com/products/product_details_66.html
Company Info:
rPeptide is a biotechnology company located in Athens, Georgia, USA, and is a market leader in providing research products (recombinant peptides and proteins, antibodies, reagents) for Alzheimer’s disease and Parkinson’s disease research. rPeptide also provides a range of custom services from molecular biology, protein expression and purification, to 13C and 15N uniform labeling of peptides and proteins.
rPeptide has a proprietary platform vector technology that enables the expression of historically difficult peptides/proteins as soluble peptides/proteins (like amylin, beta-amyloid, leptin, pro-insulin) in E. coli. For more information, contact:
Sanjay Bhardwaj
4241 Mars Hill Road,
Bogart, GA 30622, USA
Tel: 678-753-0747
Fax: 678-753-0746
